Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer

Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer, 2001, 1(3), 222-231.
[http://dx.doi.org/10.1038/35106065] [PMID: 11902577]

Harper, J.W.; Adams, P.D. Cyclin-dependent kinases. Chem. Rev., 2001, 101(8), 2511-2526.
[http://dx.doi.org/10.1021/cr0001030] [PMID: 11749386]

Malumbres, M. Cyclin-dependent kinases. Genome Biol., 2014, 15(6), 122.
[http://dx.doi.org/10.1186/gb4184] [PMID: 25180339]

Pavletich, N.P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol., 1999, 287(5), 821-828.
[http://dx.doi.org/10.1006/jmbi.1999.2640] [PMID: 10222191]

Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci., 2005, 30(11), 630-641.
[http://dx.doi.org/10.1016/j.tibs.2005.09.005] [PMID: 16236519]

Lim, S.; Kaldis, P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development, 2013, 140(15), 3079-3093.
[http://dx.doi.org/10.1242/dev.091744] [PMID: 23861057]

Kalra, S.; Joshi, G.; Munshi, A.; Kumar, R. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. Eur. J. Med. Chem., 2017, 142, 424-458.
[http://dx.doi.org/10.1016/j.ejmech.2017.08.071] [PMID: 28911822]

Cobrinik, D. Pocket proteins and cell cycle control. Oncogene, 2005, 24(17), 2796-2809.
[http://dx.doi.org/10.1038/sj.onc.1208619] [PMID: 15838516]

Ren, S.; Rollins, B.J. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell, 2004, 117(2), 239-251.
[http://dx.doi.org/10.1016/S0092-8674(04)00300-9] [PMID: 15084261]

Egloff, S.; Dienstbier, M.; Murphy, S. Updating the RNA polymerase CTD code: adding gene-specific layers. Trends Genet., 2012, 28(7), 333-341.
[http://dx.doi.org/10.1016/j.tig.2012.03.007] [PMID: 22622228]

Larochelle, S.; Amat, R.; Glover-Cutter, K.; Sansó, M.; Zhang, C.; Allen, J.J.; Shokat, K.M.; Bentley, D.L.; Fisher, R.P. Cyclin dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat. Struct. Mol. Biol., 2012, 19(11), 1108-1115.
[http://dx.doi.org/10.1038/nsmb.2399] [PMID: 23064645]

Tien, J.F.; Mazloomian, A.; Cheng, S.G.; Hughes, C.S.; Chow, C.C.T.; Canapi, L.T.; Oloumi, A.; Trigo-Gonzalez, G.; Bashashati, A.; Xu, J.; Chang, V.C.D.; Shah, S.P.; Aparicio, S.; Morin, G.B. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res., 2017, 45(11), 6698-6716.
[http://dx.doi.org/10.1093/nar/gkx187] [PMID: 28334900]

Lei, T.; Zhang, P.; Zhang, X.; Xiao, X.; Zhang, J.; Qiu, T.; Dai, Q.; Zhang, Y.; Min, L.; Li, Q.; Yin, R.; Ding, P.; Li, N.; Qu, Y.; Mu, D.; Qin, J.; Zhu, X.; Xiao, Z-X.; Li, Q. Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation. Nat. Commun., 2018, 9(1), 1876.
[http://dx.doi.org/10.1038/s41467-018-04258-w] [PMID: 29760377]

Blazek, D.; Kohoutek, J.; Bartholomeeusen, K.; Johansen, E.; Hulinkova, P.; Luo, Z.; Cimermancic, P.; Ule, J.; Peterlin, B.M. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev., 2011, 25(20), 2158-2172.
[http://dx.doi.org/10.1101/gad.16962311] [PMID: 22012619]

Greifenberg, A.K.; Hönig, D.; Pilarova, K.; Düster, R.; Bartholomeeusen, K.; Bösken, C.A.; Anand, K.; Blazek, D.; Geyer, M. Structural and functional analysis of the cdk13/cyclin k complex. Cell Rep., 2016, 14(2), 320-331.
[http://dx.doi.org/10.1016/j.celrep.2015.12.025] [PMID: 26748711]

Bostwick, B.L.; McLean, S.; Posey, J.E.; Streff, H.E.; Gripp, K.W.; Blesson, A.; Powell-Hamilton, N.; Tusi, J.; Stevenson, D.A.; Farrelly, E.; Hudgins, L.; Yang, Y.; Xia, F.; Wang, X.; Liu, P.; Walkiewicz, M.; McGuire, M.; Grange, D.K.; Andrews, M.V.; Hummel, M.; Madan-Khetarpal, S.; Infante, E.; Coban-Akdemir, Z.; Miszalski-Jamka, K.; Jefferies, J.L.; Rosenfeld, J.A.; Emrick, L.; Nugent, K.M.; Lupski, J.R.; Belmont, J.W.; Lee, B.; Lalani, S.R. Members of the Undiagnosed Diseases Network. Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders. Genome Med., 2017, 9(1), 73.
[http://dx.doi.org/10.1186/s13073-017-0463-8] [PMID: 28807008]

Carlsten, J.O.; Zhu, X.; Gustafsson, C.M. The multitalented Mediator complex. Trends Biochem. Sci., 2013, 38(11), 531-537.
[http://dx.doi.org/10.1016/j.tibs.2013.08.007] [PMID: 24074826]

Besson, A.; Dowdy, S.F.; Roberts, J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell, 2008, 14(2), 159-169.
[http://dx.doi.org/10.1016/j.devcel.2008.01.013] [PMID: 18267085]

Jeffrey, P.D.; Tong, L.; Pavletich, N.P. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev., 2000, 14(24), 3115-3125.
[http://dx.doi.org/10.1101/gad.851100] [PMID: 11124804]

Diaz-Moralli, S.; Tarrado-Castellarnau, M.; Miranda, A.; Cascante, M. Targeting cell cycle regulation in cancer therapy. Pharmacol. Ther., 2013, 138(2), 255-271.
[http://dx.doi.org/10.1016/j.pharmthera.2013.01.011] [PMID: 23356980]

Michalides, R.; van Veelen, N.; Hart, A.; Loftus, B.; Wientjens, E.; Balm, A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res., 1995, 55(5), 975-978.
[PMID: 7867006]

Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 2009, 9(3), 153-166.
[http://dx.doi.org/10.1038/nrc2602] [PMID: 19238148]

Musacchio, A.; Salmon, E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol., 2007, 8(5), 379-393.
[http://dx.doi.org/10.1038/nrm2163] [PMID: 17426725]

Cicenas, J.; Valius, M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol., 2011, 137(10), 1409-1418.
[http://dx.doi.org/10.1007/s00432-011-1039-4] [PMID: 21877198]

McDermott, M.S.J.; Sharko, A.C.; Munie, J.; Kassler, S.; Melendez, T.; Lim, C.U.; Broude, E.V. CDK7 inhibition is effective in all the subtypes of breast cancer: determinants of response and synergy with egfr inhibition. Cells, 2020, 9(3), E638.
[http://dx.doi.org/10.3390/cells9030638]] [PMID: 32155786]

Wang, Y.; Zhang, T.; Kwiatkowski, N.; Abraham, B.J.; Lee, T.I.; Xie, S.; Yuzugullu, H.; Von, T.; Li, H.; Lin, Z.; Stover, D.G.; Lim, E.; Wang, Z.C.; Iglehart, J.D.; Young, R.A.; Gray, N.S.; Zhao, J.J. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell, 2015, 163(1), 174-186.
[http://dx.doi.org/10.1016/j.cell.2015.08.063] [PMID: 26406377]

Tadesse, S.; Caldon, E.C.; Tilley, W.; Wang, S. Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. J. Med. Chem., 2019, 62(9), 4233-4251.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01469] [PMID: 30543440]

Geng, Y.; Yu, Q.; Sicinska, E.; Das, M.; Schneider, J.E.; Bhattacharya, S.; Rideout, W.M.; Bronson, R.T.; Gardner, H.; Sicinski, P.; Cyclin, E. Cyclin E ablation in the mouse. Cell, 2003, 114(4), 431-443.
[http://dx.doi.org/10.1016/S0092-8674(03)00645-7] [PMID: 12941272]

Wang, J.; Yang, T.; Xu, G.; Liu, H.; Ren, C.; Xie, W.; Wang, M. Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma. Transl. Oncol., 2016, 9(6), 548-556.
[http://dx.doi.org/10.1016/j.tranon.2016.08.007] [PMID: 27863310]

Faber, A.C.; Chiles, T.C. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. Cell Cycle, 2007, 6(23), 2982-2989.
[http://dx.doi.org/10.4161/cc.6.23.4994] [PMID: 18156799]

Trowbridge, J.M.; Rogatsky, I.; Garabedian, M.J. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc. Natl. Acad. Sci. USA, 1997, 94(19), 10132-10137.
[http://dx.doi.org/10.1073/pnas.94.19.10132] [PMID: 9294175]

Yin, X.; Yu, J.; Zhou, Y.; Wang, C.; Jiao, Z.; Qian, Z.; Sun, H.; Chen, B. Identification of CDK2 as a novel target in treatment of prostate cancer. Future Oncol., 2018, 14(8), 709-718.
[http://dx.doi.org/10.2217/fon-2017-0561] [PMID: 29323532]

Li, J-Q.; Miki, H.; Ohmori, M.; Wu, F.; Funamoto, Y. Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum. Pathol., 2001, 32(9), 945-953.
[http://dx.doi.org/10.1053/hupa.2001.27116] [PMID: 11567224]

Ahn, M.J.; Kim, B.H.; Jang, S.J.; Hong, E.K.; Lee, W.M.; Baik, H.K.; Park, H.K.; Lee, C.B.; Ki, M. Expression of cyclin D1 and cyclin E in human gastric carcinoma and its clinicopathologic significance. J. Korean Med. Sci., 1998, 13(5), 513-518.
[http://dx.doi.org/10.3346/jkms.1998.13.5.513] [PMID: 9811181]

Mohammadizadeh, F.; Hani, M.; Ranaee, M.; Bagheri, M. Role of cyclin D1 in breast carcinoma. J. Res. Med. Sci., 2013, 18(12), 1021-1025.

Michalides, R.; Hageman, P.; van Tinteren, H.; Houben, L.; Wientjens, E.; Klompmaker, R.; Peterse, J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer, 1996, 73(6), 728-734.
[http://dx.doi.org/10.1038/bjc.1996.128] [PMID: 8611372]

Foster, J.S.; Wimalasena, J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol., 1996, 10(5), 488-498.
[PMID: 8732680]

Roy, P.G.; Thompson, A.M. Cyclin D1 and breast cancer. Breast, 2006, 15(6), 718-727.
[http://dx.doi.org/10.1016/j.breast.2006.02.005] [PMID: 16675218]

Asghar, U.; Witkiewicz, A.K.; Turner, N.C.; Knudsen, E.S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov., 2015, 14(2), 130-146.
[http://dx.doi.org/10.1038/nrd4504] [PMID: 25633797]

Burkhart, D.L.; Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer, 2008, 8(9), 671-682.
[http://dx.doi.org/10.1038/nrc2399] [PMID: 18650841]

Bartkova, J.; Rezaei, N.; Liontos, M.; Karakaidos, P.; Kletsas, D.; Issaeva, N.; Vassiliou, L-V.F.; Kolettas, E.; Niforou, K.; Zoumpourlis, V.C.; Takaoka, M.; Nakagawa, H.; Tort, F.; Fugger, K.; Johansson, F.; Sehested, M.; Andersen, C.L.; Dyrskjot, L.; Ørntoft, T.; Lukas, J.; Kittas, C.; Helleday, T.; Halazonetis, T.D.; Bartek, J.; Gorgoulis, V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature, 2006, 444(7119), 633-637.
[http://dx.doi.org/10.1038/nature05268] [PMID: 17136093]

LaPak, K.M.; Burd, C.E. The molecular balancing act of p16(INK4a) in cancer and aging. Mol. Cancer Res., 2014, 12(2), 167-183.
[http://dx.doi.org/10.1158/1541-7786.MCR-13-0350] [PMID: 24136988]

Witkiewicz, A.K.; Knudsen, K.E.; Dicker, A.P.; Knudsen, E.S. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle, 2011, 10(15), 2497-2503.
[http://dx.doi.org/10.4161/cc.10.15.16776] [PMID: 21775818]

Knudsen, K.E.; Diehl, J.A.; Haiman, C.A.; Knudsen, E.S. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 2006, 25(11), 1620-1628.
[http://dx.doi.org/10.1038/sj.onc.1209371] [PMID: 16550162]

Wölfel, T.; Hauer, M.; Schneider, J.; Serrano, M.; Wölfel, C.; Klehmann-Hieb, E.; De Plaen, E.; Hankeln, T.; Meyer zum Büschenfelde, K.H.; Beach, D.A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 1995, 269(5228), 1281-1284.
[http://dx.doi.org/10.1126/science.7652577] [PMID: 7652577]

Sever-Chroneos, Z.; Angus, S.P.; Fribourg, A.F.; Wan, H.; Todorov, I.; Knudsen, K.E.; Knudsen, E.S. Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Mol. Cell. Biol., 2001, 21(12), 4032-4045.
[http://dx.doi.org/10.1128/MCB.21.12.4032-4045.2001] [PMID: 11359910]

Markey, M.P.; Angus, S.P.; Strobeck, M.W.; Williams, S.L.; Gunawardena, R.W.; Aronow, B.J.; Knudsen, E.S. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res., 2002, 62(22), 6587-6597.
[PMID: 12438254]

Polyak, K.; Lee, M-H.; Erdjument-Bromage, H.; Koff, A.; Roberts, J.M.; Tempst, P.; Massagué, J. Cloning of p27Kip1, a cyclin dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 1994, 78(1), 59-66.
[http://dx.doi.org/10.1016/0092-8674(94)90572-X] [PMID: 8033212]

Wu, C-L.; Kirley, S.D.; Xiao, H.; Chuang, Y.; Chung, D.C.; Zukerberg, L.R. Cables enhances cdk2 tyrosine 15 phosphorylation by Wee1, inhibits cell growth, and is lost in many human colon and squamous cancers. Cancer Res., 2001, 61(19), 7325-7332.
[PMID: 11585773]

Scaltriti, M.; Eichhorn, P.J.; Cortés, J.; Prudkin, L.; Aura, C.; Jiménez, J.; Chandarlapaty, S.; Serra, V.; Prat, A.; Ibrahim, Y.H.; Guzmán, M.; Gili, M.; Rodríguez, O.; Rodríguez, S.; Pérez, J.; Green, S.R.; Mai, S.; Rosen, N.; Hudis, C.; Baselga, J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl. Acad. Sci. USA, 2011, 108(9), 3761-3766.
[http://dx.doi.org/10.1073/pnas.1014835108] [PMID: 21321214]

Lukas, J.; Herzinger, T.; Hansen, K.; Moroni, M.C.; Resnitzky, D.; Helin, K.; Reed, S.I.; Bartek, J. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev., 1997, 11(11), 1479-1492.
[http://dx.doi.org/10.1101/gad.11.11.1479] [PMID: 9192874]

Hammerman, P.S.; Lawrence, M.S.; Voet, D.; Jing, R.; Cibulskis, K.; Sivachenko, A.; Stojanov, P.; McKenna, A.; Lander, E.S.; Gabriel, S.; Getz, G.; Sougnez, C.; Imielinski, M.; Helman, E.; Hernandez, B.; Pho, N.H.; Meyerson, M.; Chu, A.; Chun, H-J.E.; Mungall, A.J.; Pleasance, E.; Gordon Robertson, A.; Sipahimalani, P.; Stoll, D.; Balasundaram, M.; Birol, I.; Butterfield, Y.S.N.; Chuah, E.; Coope, R.J.N.; Corbett, R.; Dhalla, N.; Guin, R.; He, A.; Hirst, C.; Hirst, M.; Holt, R.A.; Lee, D.; Li, H.I.; Mayo, M.; Moore, R.A.; Mungall, K.; Ming Nip, K.; Olshen, A.; Schein, J.E.; Slobodan, J.R.; Tam, A.; Thiessen, N.; Varhol, R.; Zeng, T.; Zhao, Y.; Jones, S.J.M.; Marra, M.A.; Saksena, G.; Cherniack, A.D.; Schumacher, S.E.; Tabak, B.; Carter, S.L.; Pho, N.H.; Nguyen, H.; Onofrio, R.C.; Crenshaw, A.; Ardlie, K.; Beroukhim, R.; Winckler, W.; Hammerman, P.S.; Getz, G.; Meyerson, M.; Protopopov, A.; Zhang, J.; Hadjipanayis, A.; Lee, S.; Xi, R.; Yang, L.; Ren, X.; Zhang, H.; Shukla, S.; Chen, P-C.; Haseley, P.; Lee, E.; Chin, L.; Park, P.J.; Kucherlapati, R.; Socci, N.D.; Liang, Y.; Schultz, N.; Borsu, L.; Lash, A.E.; Viale, A.; Sander, C.; Ladanyi, M.; Todd Auman, J.; Hoadley, K.A.; Wilkerson, M.D.; Shi, Y.; Liquori, C.; Meng, S.; Li, L.; Turman, Y.J.; Topal, M.D.; Tan, D.; Waring, S.; Buda, E.; Walsh, J.; Jones, C.D.; Mieczkowski, P.A.; Singh, D.; Wu, J.; Gulabani, A.; Dolina, P.; Bodenheimer, T.; Hoyle, A.P.; Simons, J.V.; Soloway, M.G.; Mose, L.E.; Jefferys, S.R.; Balu, S.; O’Connor, B.D.; Prins, J.F.; Liu, J.; Chiang, D.Y.; Neil Hayes, D.; Perou, C.M.; Cope, L.; Danilova, L.; Weisenberger, D.J.; Maglinte, D.T.; Pan, F.; Van Den Berg, D.J.; Triche Jr, T.; Herman, J.G.; Baylin, S.B.; Laird, P.W.; Getz, G.; Noble, M.; Voet, D.; Saksena, G.; Gehlenborg, N.; DiCara, D.; Zhang, J.; Zhang, H.; Wu, C-J.; Liu, Y. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature, 2012, 489(7417), 519-525.
[http://dx.doi.org/10.1038/nature11404] [PMID: 22960745]

Weinstein, J.N.; Akbani, R.; Broom, B.M.; Wang, W.; Verhaak, R.G.W.; McConkey, D.; Lerner, S.; Morgan, M.; Creighton, C.J.; Smith, C.; Kwiatkowski, D.J.; Cherniack, A.D.; Kim, J.; Sekhar Pedamallu, C.; Noble, M.S.; Al-Ahmadie, H.A.; Reuter, V.E.; Rosenberg, J.E.; Bajorin, D.F.; Bochner, B.H.; Solit, D.B.; Koppie, T.; Robinson, B.; Gordenin, D.A.; Fargo, D.; Klimczak, L.J.; Roberts, S.A.; Au, J.; Laird, P.W.; Hinoue, T.; Schultz, N.; Ramirez, R.; Hansel, D.; Hoadley, K.A.; Kim, W.Y.; Damrauer, J.S.; Baylin, S.B.; Mungall, A.J.; Gordon Robertson, A.; Chu, A.; Kwiatkowski, D.J.; Sougnez, C.; Cibulskis, K.; Lichtenstein, L.; Sivachenko, A.; Stewart, C.; Lawrence, M.S.; Getz, G.; Lander, E.; Gabriel, S.B.; Creighton, C.J.; Donehower, L.; Cherniack, A.D.; Kim, J.; Carter, S.L.; Saksena, G.; Schumacher, S.E.; Sougnez, C.; Freeman, S.S.; Jung, J.; Sekhar Pedamallu, C.; Bhatt, A.S.; Pugh, T.; Getz, G.; Beroukhim, R.; Gabriel, S.B.; Meyerson, M.; Mungall, A.J.; Gordon Robertson, A.; Chu, A.; Ally, A.; Balasundaram, M.; Butterfield, Y.S.N.; Dhalla, N.; Hirst, C.; Holt, R.A.; Jones, S.J.M.; Lee, D.; Li, H.I.; Marra, M.A.; Mayo, M.; Moore, R.A.; Schein, J.E.; Sipahimalani, P.; Tam, A.; Thiessen, N.; Wong, T.; Wye, N.; Bowlby, R.; Chuah, E.; Guin, R.; Jones, S.J.M.; Marra, M.A.; Hinoue, T.; Shen, H.; Bootwalla, M.S.; Triche Jr, T.; Lai, P.H.; Van Den Berg, D.J.; Weisenberger, D.J.; Laird, P.W.; Hansel, D.; Hoadley, K.A.; Balu, S.; Bodenheimer, T.; Damrauer Alan, P. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 2014, 507(7492), 315-322.
[http://dx.doi.org/10.1038/nature12965] [PMID: 24476821]

Leone, P.E.; Walker, B.A.; Jenner, M.W.; Chiecchio, L.; Dagrada, G.; Protheroe, R.K.M.; Johnson, D.C.; Dickens, N.J.; Brito, J.L.; Else, M.; Gonzalez, D.; Ross, F.M.; Chen-Kiang, S.; Davies, F.E.; Morgan, G.J. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin. Cancer Res., 2008, 14(19), 6033-6041.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0347] [PMID: 18829482]

Bell, D.; Berchuck, A.; Birrer, M.; Chien, J.; Cramer, D.W.; Dao, F.; Dhir, R.; DiSaia, P.; Gabra, H.; Glenn, P.; Godwin, A.K.; Gross, J.; Hartmann, L.; Huang, M.; Huntsman, D.G.; Iacocca, M.; Imielinski, M.; Kalloger, S.; Karlan, B.Y.; Levine, D.A.; Mills, G.B.; Morrison, C.; Mutch, D.; Olvera, N.; Orsulic, S.; Park, K.; Petrelli, N.; Rabeno, B.; Rader, J.S.; Sikic, B.I.; Smith-McCune, K.; Sood, A.K.; Bowtell, D.; Penny, R.; Testa, J.R.; Chang, K.; Creighton, C.J.; Dinh, H.H.; Drummond, J.A.; Fowler, G.; Gunaratne, P.; Hawes, A.C.; Kovar, C.L.; Lewis, L.R.; Morgan, M.B.; Newsham, I.F.; Santibanez, J.; Reid, J.G.; Trevino, L.R.; Wu, Y.Q.; Wang, M.; Muzny, D.M.; Wheeler, D.A.; Gibbs, R.A.; Getz, G.; Lawrence, M.S.; Cibulskis, K.; Sivachenko, A.Y.; Sougnez, C.; Voet, D.; Wilkinson, J.; Bloom, T.; Ardlie, K.; Fennell, T.; Baldwin, J.; Nichol, R.; Fisher, S.; Gabriel, S.; Lander, E.S.; Ding, L.; Fulton, R.S.; Koboldt, D.C.; McLellan, M.D.; Wylie, T.; Walker, J.; O’Laughlin, M.; Dooling, D.J.; Fulton, L.; Abbott, R.; Dees, N.D.; Zhang, Q.; Kandoth, C.; Wendl, M.; Schierding, W.; Shen, D.; Harris, C.C.; Schmidt, H.; Kalicki, J.; Delehaunty, K.D.; Fronick, C.C.; Demeter, R.; Cook, L.; Wallis, J.W.; Lin, L.; Magrini, V.J.; Hodges, J.S.; Eldred, J.M.; Smith, S.M.; Pohl, C.S.; Vandin, F.; Upfal, E.; Raphael, B.J.; Weinstock, G.M.; Mardis, E.R.; Wilson, R.K.; Meyerson, M.; Winckler, W.; Getz, G.; Verhaak, R.G.W.; Carter, S.L.; Mermel, C.H.; Saksena, G.; Nguyen, H.; Onofrio, R.C.; Lawrence, M.S.; Hubbard, D.; Gupta, S.; Crenshaw, A.; Ramos, A.H.; Ardlie, K.; Chin, L.; Protopopov, A.; Zhang, J.; Kim, T.M.; Perna, I.; Xiao, Y.; Zhang, H.; Ren, G.; Sathiamoorthy, N.; Park, R.W.; Lee, E.; Park, P.J.; Kucherlapati, R.; Absher, D.M.; Waite, L.; Sherlock, G.; Brooks, J.D.; Li, J.Z.; Xu, J.; Myers, R.M.; Laird, P.W.; Cope, L.; Herman, J.G.; Shen, H.; Weisenberger, D.J.; Noushmehr, H.; Pan, F.; Triche, T., Jr; Berman, B.P.; Van Den Berg, D.J.; Buckley, J.; Baylin, S.B.; Spellman, P.T.; Purdom, E.; Neuvial, P.; Bengtsson, H.; Jakkula, L.R.; Durinck, S.; Han, J.; Dorton, S.; Marr, H.; Choi, Y.G.; Wang, V.; Wang, N.J.; Ngai, J.; Conboy, J.G.; Parvin, B.; Feiler, H.S.; Speed, T.P.; Gray, J.W.; Levine, D.A.; Socci, N.D.; Liang, Y.; Taylor, B.S.; Schultz, N.; Borsu, L.; Lash, A.E.; Brennan, C.; Viale, A.; Sander, C.; Ladanyi, M.; Hoadley, K.A.; Meng, S.; Du, Y.; Shi, Y.; Li, L.; Turman, Y.J.; Zang, D.; Helms, E.B.; Balu, S.; Zhou, X.; Wu, J.; Topal, M.D.; Hayes, D.N.; Perou, C.M.; Getz, G.; Voet, D.; Saksena, G.; Zhang, J.; Zhang, H.; Wu, C.J.; Shukla, S.; Cibulskis, K.; Lawrence, M.S.; Sivachenko, A.; Jing, R.; Park, R.W.; Liu, Y.; Park, P.J.; Noble, M.; Chin, L.; Carter, H.; Kim, D.; Samayoa, J.; Karchin, R.; Spellman, P.T.; Purdom, E.; Neuvial, P.; Bengtsson, H.; Durinck, S.; Han, J.; Korkola, J.E.; Heiser, L.M.; Cho, R.J.; Hu, Z.; Parvin, B.; Speed, T.P.; Gray, J.W.; Schultz, N.; Cerami, E.; Taylor, B.S.; Olshen, A.; Reva, B.; Antipin, Y.; Shen, R.; Mankoo, P.; Sheridan, R.; Ciriello, G.; Chang, W.K.; Bernanke, J.A.; Borsu, L.; Levin, D.A.; Ladanyi, M.; Sander, C.; Haussler, D.; Benz, C.C.; Stuart, J.M.; Benz, S.C.; Sanborn, J.Z.; Vaske, C.J.; Zhu, J.; Szeto, C.; Scott, G.K.; Yau, C.; Hoadley, K.A.; Du, Y.; Balu, S.; Hayes, D.N.; Perou, C.M.; Wilkerson, M.D.; Zhang, N.; Akbani, R.; Baggerly, K.A.; Yung, W.K.; Mills, G.B.; Weinstein, J.N.; Penny, R.; Shelton, T.; Grimm, D.; Hatfield, M.; Morris, S.; Yena, P.; Rhodes, P.; Sherman, M.; Paulauskis, J.; Millis, S.; Kahn, A.; Greene, J.M. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 2011, 474(7353), 609-615.
[http://dx.doi.org/10.1038/nature10166] [PMID: 21720365]

Cazier, J.B.; Rao, S.R.; McLean, C.M.; Walker, A.K.; Wright, B.J.; Jaeger, E.E.M.; Kartsonaki, C.; Marsden, L.; Yau, C.; Camps, C.; Kaisaki, P.; Taylor, J.; Catto, J.W.; Tomlinson, I.P.; Kiltie, A.E.; Hamdy, F.C.; Buck, D.; Cazier, J-B.; Copley, R.; Cornall, R.; Donnelly, P.; Fiddy, S.; Green, A.; Gregory, L.; Grocock, R.; Hatton, E.; Holmes, C.; Hughes, L.; Humburg, P.; Humphray, S.; Kanapin, A.; Kingsbury, Z.; Knight, J.; Lamble, S.; Lise, S.; Lonie, L.; Lunter, G.; Martin, H.; Murray, L.; McCarthy, D.; McVean, G.; Pagnamenta, A.; Piazza, P.; Polanco, G.; Ratcliffe, P.; Rimmer, A.; Sahgal, N.; Taylor, J.; Tomlinson, I.; Trebes, A.; Wilkie, A.; Wright, B.; Yau, C.; Taylor, J.; Catto, J.W.; Tomlinson, I.P.M.; Kiltie, A.E.; Hamdy, F.C. Oxford-Illumina WGS500 Consortium. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat. Commun., 2014, 5(1), 3756.
[http://dx.doi.org/10.1038/ncomms4756] [PMID: 24777035]

Abbas, T.; Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer, 2009, 9(6), 400-414.
[http://dx.doi.org/10.1038/nrc2657] [PMID: 19440234]

Caffo, O.; Doglioni, C.; Veronese, S.; Bonzanini, M.; Marchetti, A.; Buttitta, F.; Fina, P.; Leek, R.; Morelli, L.; Palma, P.D.; Harris, A.L.; Barbareschi, M. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res., 1996, 2(9), 1591-1599.
[PMID: 9816338]

Dhavan, R.; Tsai, L-H. A decade of CDK5. Nat. Rev. Mol. Cell Biol., 2001, 2(10), 749-759.
[http://dx.doi.org/10.1038/35096019] [PMID: 11584302]

Su, S.C.; Tsai, L-H. Cyclin-dependent kinases in brain development and disease. Annu. Rev. Cell Dev. Biol., 2011, 27(1), 465-491.
[http://dx.doi.org/10.1146/annurev-cellbio-092910-154023] [PMID: 21740229]

Zheng, Y-L.; Amin, N.D.; Hu, Y-F.; Rudrabhatla, P.; Shukla, V.; Kanungo, J.; Kesavapany, S.; Grant, P.; Albers, W.; Pant, H.C. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J. Biol. Chem., 2010, 285(44), 34202-34212.
[http://dx.doi.org/10.1074/jbc.M110.134643] [PMID: 20720012]

Lau, L-F.; Ahlijanian, M.K. Role of cdk5 in the pathogenesis of Alzheimer’s disease. Neurosignals, 2003, 12(4-5), 209-214.
[http://dx.doi.org/10.1159/000074622] [PMID: 14673207]

Dixit, A.B.; Banerjee, J.; Tripathi, M.; Sarkar, C.; Chandra, P.S. Synaptic roles of cyclin-dependent kinase 5 & its implications in epilepsy. Indian J. Med. Res., 2017, 145(2), 179-188.
[PMID: 28639593]

Shah, K.; Lahiri, D.K. Cdk5 activity in the brain - multiple paths of regulation. J. Cell Sci., 2014, 127(Pt 11), 2391-2400.
[http://dx.doi.org/10.1242/jcs.147553] [PMID: 24879856]

Schang, L.M. Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother., 2002, 50(6), 779-792.
[http://dx.doi.org/10.1093/jac/dkf227] [PMID: 12460995]

Schang, L.M. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr. Drug Targets Infect. Disord., 2005, 5(1), 29-37.
[http://dx.doi.org/10.2174/1568005053174609] [PMID: 15777196]

Wang, S.; Fischer, P.M. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol. Sci., 2008, 29(6), 302-313.
[http://dx.doi.org/10.1016/j.tips.2008.03.003] [PMID: 18423896]

Nekhai, S.; Zhou, M.; Fernandez, A.; Lane, W.S.; Lamb, N.J.C.; Brady, J.; Kumar, A. HIV-1 Tat-associated RNA polymerase C terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem. J., 2002, 364(Pt 3), 649-657.
[http://dx.doi.org/10.1042/bj20011191] [PMID: 12049628]

Geyer, J.A.; Prigge, S.T.; Waters, N.C. Targeting malaria with specific CDK inhibitors. Biochim. Biophys. Acta, 2005, 1754(1-2), 160-170.
[http://dx.doi.org/10.1016/j.bbapap.2005.07.031] [PMID: 16185941]

Ward, P.; Equinet, L.; Packer, J.; Doerig, C. Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics, 2004, 5(1), 79.
[http://dx.doi.org/10.1186/1471-2164-5-79] [PMID: 15479470]

Hong, H.; Zeng, Y.; Jian, W.; Li, L.; Lin, L.; Mo, Y.; Liu, M.; Fang, S.; Xia, Y. CDK7 inhibition suppresses rheumatoid arthritis inflammation via blockage of NF-κB activation and IL-1β/IL-6 secretion. J. Cell. Mol. Med., 2018, 22(2), 1292-1301.
[PMID: 29083085]

U.S. Food & Drug Administration. FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. Available from:. https://www.fda.gov/drugs/drugsafety-and-availability/fda-warns-about-rare-severe-lunginflammation- ibrance-kisqali-and-verzenio-breast-cancer (Accessed on Feb 02, 2020).

Do, K.T.; Chau, N.; Wolanski, A.; Beardslee, B.; Hassinger, F.; Bhushan, K.; Pruitt-Thompson, S.; Scotton, A.; Frame, S.; Zheleva, D.I.; Blake, D.; Chiao, J.; Shapiro, G.I. Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). Cancer Res., 2018, 78(13)(Suppl.), CT037-CT037.

Beaver, J.A.; Amiri-Kordestani, L.; Charlab, R.; Chen, W.; Palmby, T.; Tilley, A.; Zirkelbach, J.F.; Yu, J.; Liu, Q.; Zhao, L.; Crich, J.; Chen, X.H.; Hughes, M.; Bloomquist, E.; Tang, S.; Sridhara, R.; Kluetz, P.G.; Kim, G.; Ibrahim, A.; Pazdur, R.; Cortazar, P. FDA approval: Palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, her2-negative metastatic breast cancer. Clin. Cancer Res., 2015, 21(21), 4760-4766.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1185] [PMID: 26324739]

Laderian, B.; Fojo, T. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib. Semin. Oncol., 2017, 44(6), 395-403.
[http://dx.doi.org/10.1053/j.seminoncol.2018.03.006] [PMID: 29935901]

Long, F.; He, Y.; Fu, H.; Li, Y.; Bao, X.; Wang, Q.; Wang, Y.; Xie, C.; Lou, L. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sci., 2019, 110(4), 1420-1430.
[http://dx.doi.org/10.1111/cas.13957] [PMID: 30724426]

Bisi, J.E.; Sorrentino, J.A.; Roberts, P.J.; Tavares, F.X.; Strum, J.C. Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression. Mol. Cancer Ther., 2016, 15(5), 783-793.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0775] [PMID: 26826116]

Bisi, J.E.; Sorrentino, J.A.; Jordan, J.L.; Darr, D.D.; Roberts, P.J.; Tavares, F.X.; Strum, J.C. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget, 2017, 8(26), 42343-42358.
[http://dx.doi.org/10.18632/oncotarget.16216] [PMID: 28418845]

Anon., New method for synthesis of 6-(difluoromethyl)-8-[(1R,2R)- 2-hydroxy2-methylcyclopentyl]-2-[1-(methylsulfonyl)-piperidin- 4-yl]aminopyrido[2,3-d]pyrimidin-7(8H)-one (PF-06873600). IP.com J. 2019, 19(7A), 1-3.

Behenna, D.C.; Chen, P.; Freeman-Cook, K.D.; Hoffman, R.L.; Jalaie, M.; Nagata, A.; Nair, S.K.; Ninkovic, S.; Ornelas, M.A.; Palmer, C.L.; Rui, E.Y. CDK2/4/6 inhibitors. U.S. Patent 20180044344A1, Feb 15th 2018.

Cicenas, J.; Kalyan, K.; Sorokinas, A.; Stankunas, E.; Levy, J.; Meskinyte, I.; Stankevicius, V.; Kaupinis, A.; Valius, M. Roscovitine in cancer and other diseases. Ann. Transl. Med., 2015, 3(10), 135.
[PMID: 26207228]

Seftel, M.D.; Kuruvilla, J.; Kouroukis, T.; Banerji, V.; Fraser, G.; Crump, M.; Kumar, R.; Chalchal, H.I.; Salim, M.; Laister, R.C.; Crocker, S.; Gibson, S.B.; Toguchi, M.; Lyons, J.F.; Xu, H.; Powers, J.; Sederias, J.; Seymour, L.; Hay, A.E. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leuk. Lymphoma, 2017, 58(6), 1358-1365.
[http://dx.doi.org/10.1080/10428194.2016.1239259] [PMID: 27750483]

Kumar, S.K.; LaPlant, B.; Chng, W.J.; Zonder, J.; Callander, N.; Fonseca, R.; Fruth, B.; Roy, V.; Erlichman, C.; Stewart, A.K. Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood, 2015, 125(3), 443-448.
[http://dx.doi.org/10.1182/blood-2014-05-573741] [PMID: 25395429]

Cassaday, R.D.; Goy, A.; Advani, S.; Chawla, P.; Nachankar, R.; Gandhi, M.; Gopal, A.K. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin. Lymphoma Myeloma Leuk., 2015, 15(7), 392-397.
[http://dx.doi.org/10.1016/j.clml.2015.02.021] [PMID: 25816934]

Hirte, H.; Raghunadharao, D.; Baetz, T.; Hotte, S.; Rajappa, S.; Iacobucci, A.; Sharma, S.; Parikh, H.; Kulkarni, S.; Patil, S.; Padigaru, M.; Gaston, S. A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. Mol. Cancer Ther., 2007, 6(11)(Suppl.), A112.

Joshi, K.S.; Rathos, M.J.; Joshi, R.D.; Sivakumar, M.; Mascarenhas, M.; Kamble, S.; Lal, B.; Sharma, S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol. Cancer Ther., 2007, 6(3), 918-925.
[http://dx.doi.org/10.1158/1535-7163.MCT-06-0613] [PMID: 17363486]

Deep, A.; Marwaha, R.K.; Marwaha, M.G. Jyoti; Nandal, R.; Sharma, A.K. Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review. New J. Chem., 2018, 42(23), 18500-18507.
[http://dx.doi.org/10.1039/C8NJ04306J]

Besse, B.; Garassino, M.C.; Rajan, A.; Novello, S.; Mazieres, J.; Weiss, G.J.; Kocs, D.M.; Barnett, J.M.; Davite, C.; Crivori, P.; Giaccone, G. Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients. J. Clin. Oncol., 2018, 36(15_suppl), 8519-8519.

Ainscow, E.K.; Leishman, A.; Sullivan, E.; Li, B.; Gallagher, W.; Peall, A.; Clark, K.; Thomson, S.; Ali, S.; Coombes, R.C.; Bahl, A. Abstract 4834: CT7001: An orally bioavailable CDK7 inhibitor is apotential therapy for breast, small-cell lung and haematological cancers. Cancer Res., 2018, 78(13)(Suppl.), 4834.

Goh, K.C.; Novotny-Diermayr, V.; Hart, S.; Ong, L.C.; Loh, Y.K.; Cheong, A.; Tan, Y.C.; Hu, C.; Jayaraman, R.; William, A.D.; Sun, E.T.; Dymock, B.W.; Ong, K.H.; Ethirajulu, K.; Burrows, F.; Wood, J.M. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia, 2012, 26(2), 236-243.
[http://dx.doi.org/10.1038/leu.2011.218] [PMID: 21860433]

U.S. National Library of Medicine Evaluation of safety and efficacy in bey1107 in monotherapy gemcitabine combination in patient with pancreatic cancer., https://clinicaltrials.gov/ct2/show/NCT03579836 (Feb 06, 2020).

Siemeister, G.; Lücking, U.; Wengner, A.M.; Lienau, P.; Steinke, W.; Schatz, C.; Mumberg, D.; Ziegelbauer, K. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol. Cancer Ther., 2012, 11(10), 2265-2273.
[http://dx.doi.org/10.1158/1535-7163.MCT-12-0286] [PMID: 22821149]

Lücking, U.; Scholz, A.; Lienau, P.; Siemeister, G.; Kosemund, D.; Bohlmann, R.; Briem, H.; Terebesi, I.; Meyer, K.; Prelle, K.; Denner, K.; Bömer, U.; Schäfer, M.; Eis, K.; Valencia, R.; Ince, S.; von Nussbaum, F.; Mumberg, D.; Ziegelbauer, K.; Klebl, B.; Choidas, A.; Nussbaumer, P.; Baumann, M.; Schultz-Fademrecht, C.; Rühter, G.; Eickhoff, J.; Brands, M. Identification of atuveciclib (BAY 1143572), the first highly selective, clinical ptefb/cdk9 inhibitor for the treatment of cancer. ChemMedChem, 2017, 12(21), 1776-1793.
[http://dx.doi.org/10.1002/cmdc.201700447] [PMID: 28961375]

Luecking, U.T.; Scholz, A.; Kosemund, D.; Bohlmann, R.; Briem, H.; Lienau, P.; Siemeister, G.; Terebesi, I.; Meyer, K.; Prelle, K.; Valencia, R.; Ince, S.; Nussbaum, F.v.; Mumberg, D.; Ziegelbauer, K.; Brands, M. Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops. Cancer Res., 2017, 77(13)(Suppl.), 984.

Walsby, E.; Lazenby, M.; Pepper, C.; Burnett, A.K. The cyclin dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia, 2011, 25(3), 411-419.
[http://dx.doi.org/10.1038/leu.2010.290] [PMID: 21212792]

Gupta, S.; Jain, M.M.; Maru, A.; Nag, S.M.; Somani, N.; Mehta, A.O.; Kulkarni, S.; Acharya, S.A.; Dhobe, P.; Jadhav, N. A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. J. Clin. Oncol., 2012, 30(15_suppl), 3011-3011.
[http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3011]

U.S. National Library of Medicine A phase I study of TQB3616 on tolerance and pharmacokinetics., Available from:. https://clinicaltrials.gov/ct2/show/NCT03850873 (Feb 05,2020).

Zhang, C.C.; Kephart, S.; McAlpine, I.; Nonomiya, J.; Higgins, J.; Arango, M.E.; Yan, Z.; Knighton, D.; Ferre, R.A.; Tikhe, J.; Verkhivker, G.; Xu, M.; Romines, W.; Palmer, C.; Park, J.; Reich, S.; Chong, W.; Li, L.; Los, G.; Lewis, C. AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity. Cancer Res., 2005, 65(9)(Suppl.), 1045.
[PMID: 15867387]

U.S. National Library of Medicine. A study of cs3002 in advanced solid tumors., Available from:. https://clinicaltrials.gov/ct2/show/NCT04162301 (Feb 05, 2020).

U.S. National Library of Medicine. A phase 1 study of hs-10342 in patients with advanced solid tumor., Available from:. https://clinicaltrials.gov/ct2/show/NCT04060511 (Feb 06, 2020).

Hu, S.; Marineau, J.J.; Rajagopal, N.; Hamman, K.B.; Choi, Y.J.; Schmidt, D.R.; Ke, N.; Johannessen, L.; Bradley, M.J.; Orlando, D.A.; Alnemy, S.R.; Ren, Y.; Ciblat, S.; Winter, D.K.; Kabro, A.; Sprott, K.T.; Hodgson, J.G.; Fritz, C.C.; Carulli, J.P.; di Tomaso, E.; Olson, E.R. Discovery and characterization of SY-1365, a selective, covalent inhibitor of cdk7. Cancer Res., 2019, 79(13), 3479-3491.
[http://dx.doi.org/10.1158/0008-5472.CAN-19-0119] [PMID: 31064851]

Cidado, J.; Boiko, S.; Proia, T.; Ferguson, D.; Criscione, S.W.; San Martin, M.; Pop-Damkov, P.; Su, N.; Roamio Franklin, V.N.; Sekhar Reddy Chilamakuri, C.; D’Santos, C.S.; Shao, W.; Saeh, J.C.; Koch, R.; Weinstock, D.M.; Zinda, M.; Fawell, S.E.; Drew, L. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin. Cancer Res., 2020, 26(4), 922-934.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-1853] [PMID: 31699827]

Byth, K.F.; Thomas, A.; Hughes, G.; Forder, C.; McGregor, A.; Geh, C.; Oakes, S.; Green, C.; Walker, M.; Newcombe, N.; Green, S.; Growcott, J.; Barker, A.; Wilkinson, R.W. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol. Cancer Ther., 2009, 8(7), 1856-1866.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0836] [PMID: 19509270]

Rzymski, T.; Mikula, M.; Żyłkiewicz, E.; Dreas, A.; Wiklik, K.; Gołas, A.; Wójcik, K.; Masiejczyk, M.; Wróbel, A.; Dolata, I.; Kitlińska, A.; Statkiewicz, M.; Kuklinska, U.; Goryca, K.; Sapała, Ł.; Grochowska, A.; Cabaj, A.; Szajewska-Skuta, M.; Gabor- Worwa, E.; Kucwaj, K.; Białas, A.; Radzimierski, A.; Combik, M.; Woyciechowski, J.; Mikulski, M.; Windak, R.; Ostrowski, J.; Brzózka, K. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget, 2017, 8(20), 33779-33795.
[http://dx.doi.org/10.18632/oncotarget.16810] [PMID: 28422713]

Grossman, S.A.; Ye, X.; Peereboom, D.; Rosenfeld, M.R.; Mikkelsen, T.; Supko, J.G.; Desideri, S. Adult Brain Tumor Consortium. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro-oncol., 2012, 14(4), 511-517.
[http://dx.doi.org/10.1093/neuonc/nor230] [PMID: 22323663]

Kim, W.; Haws, H.; Peterson, P.; Whatcott, C.J.; Weitman, S.; Warner, S.L.; Bearss, D.J.; Siddiqui-Jain, A. Abstract 5133: TP -1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. Cancer Res., 2017, 77(13)(Suppl.), 5133.

U.S. National Library of Medicine. Study of bcd-115 in women with er(+) her2(-) local advanced and metastatic breast cancer, Available from:. https://clinicaltrials.gov/ct2/show/NCT03065010 (Feb 05, 2020).

Locatelli, G.; Bosotti, R.; Ciomei, M.; Brasca, M.G.; Calogero, R.; Mercurio, C.; Fiorentini, F.; Bertolotti, M.; Scacheri, E.; Scaburri, A.; Galvani, A.; Pesenti, E.; De Baere, T.; Soria, J-C.; Lazar, V.; Isacchi, A. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA- 793887 in tumor and skin biopsies from a phase I clinical study. Mol. Cancer Ther., 2010, 9(5), 1265-1273.
[http://dx.doi.org/10.1158/1535-7163.MCT-09-1163] [PMID: 20423997]

DePinto, W.; Chu, X-J.; Yin, X.; Smith, M.; Packman, K.; Goelzer, P.; Lovey, A.; Chen, Y.; Qian, H.; Hamid, R.; Xiang, Q.; Tovar, C.; Blain, R.; Nevins, T.; Higgins, B.; Luistro, L.; Kolinsky, K.; Felix, B.; Hussain, S.; Heimbrook, D. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer Ther., 2006, 5(11), 2644-2658.
[http://dx.doi.org/10.1158/1535-7163.MCT-06-0355] [PMID: 17121911]

U.S. National Library of Medicine. A phase I study of bpi-16350 in patients with advanced solid tumor., Available from:. https://clinicaltrials.gov/ct2/show/NCT03791112 (Feb 05, 2020).

Lin, S.; Zhao, X.; Li, T.; Zhang, H.; Tan, H.; Wang, X.; Jiang, L.; Liu, Y.; Sun, J.; Linghu, L.; Liu, Q.; Li, Z.; Zhang, W.; Wang, W. Abstract 4425: FCN-437: A novel, potent and selective oral inhibitor of CDK4/6 for the treatment of solid tumors. Cancer Res., 2019, 79(13)(Suppl.), 4425.

Wang, Y.; Zhi, Y.; Jin, Q.; Lu, S.; Lin, G.; Yuan, H.; Yang, T.; Wang, Z.; Yao, C.; Ling, J.; Guo, H.; Li, T.; Jin, J.; Li, B.; Zhang, L.; Chen, Y.; Lu, T. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin- 4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1Hpyrazole- 3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute myelocytic leukemia. J. Med. Chem., 2018, 61(4), 1499-1518.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01261] [PMID: 29357250]

Richardson, G.E.; Vaishampayan, U.N.; Lin, L.; Bozon, V.; Hui, A.-M.; Williamson, S.K. A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors. J. Clin. Oncol., 2019, 37(15_suppl), TPS3150-TPS3150.

Bharate, S.B.; Kumar, V.; Jain, S.K.; Mintoo, M.J.; Guru, S.K.; Nuthakki, V.K.; Sharma, M.; Bharate, S.S.; Gandhi, S.G.; Mondhe, D.M.; Bhushan, S.; Vishwakarma, R.A. Discovery and preclinical development of iiim-290, an orally active potent cyclin-dependent kinase inhibitor. J. Med. Chem., 2018, 61(4), 1664-1687.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01765] [PMID: 29370702]

Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y-S.; Sonke, G.S.; Paluch-Shimon, S.; Campone, M.; Blackwell, K.L.; André, F.; Winer, E.P.; Janni, W.; Verma, S.; Conte, P.; Arteaga, C.L.; Cameron, D.A.; Petrakova, K.; Hart, L.L.; Villanueva, C.; Chan, A.; Jakobsen, E.; Nusch, A.; Burdaeva, O.; Grischke, E-M.; Alba, E.; Wist, E.; Marschner, N.; Favret, A.M.; Yardley, D.; Bachelot, T.; Tseng, L-M.; Blau, S.; Xuan, F.; Souami, F.; Miller, M.; Germa, C.; Hirawat, S.; O’Shaughnessy, J. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N. Engl. J. Med., 2016, 375(18), 1738-1748.
[http://dx.doi.org/10.1056/NEJMoa1609709] [PMID: 27717303]

Varella, L.; Eziokwu, A.S.; Jia, X.; Kruse, M.; Moore, H.C.F.; Budd, G.T.; Abraham, J.; Montero, A.J. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res. Treat., 2019, 176(2), 429-434.
[http://dx.doi.org/10.1007/s10549-019-05176-1] [PMID: 30895534]

Kelland, L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin. Investig. Drugs, 2000, 9(12), 2903-2911.
[http://dx.doi.org/10.1517/13543784.9.12.2903] [PMID: 11093360]

Turner, N.C.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Huang Bartlett, C.; Zhang, K.; Giorgetti, C.; Randolph, S.; Koehler, M.; Cristofanilli, M. PALOMA3 study group. palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med., 2015, 373(3), 209-219.
[http://dx.doi.org/10.1056/NEJMoa1505270] [PMID: 26030518]

Goetz, M.P.; Toi, M.; Campone, M.; Sohn, J.; Paluch-Shimon, S.; Huober, J.; Park, I.H.; Trédan, O.; Chen, S-C.; Manso, L.; Freedman, O.C.; Garnica Jaliffe, G.; Forrester, T.; Frenzel, M.; Barriga, S.; Smith, I.C.; Bourayou, N.; Di Leo, A. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol., 2017, 35(32), 3638-3646.
[http://dx.doi.org/10.1200/JCO.2017.75.6155] [PMID: 28968163]

Le Tourneau, C.; Faivre, S.; Laurence, V.; Delbaldo, C.; Vera, K.; Girre, V.; Chiao, J.; Armour, S.; Frame, S.; Green, S.R.; Gianella- Borradori, A.; Diéras, V.; Raymond, E. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur. J. Cancer, 2010, 46(18), 3243-3250.
[http://dx.doi.org/10.1016/j.ejca.2010.08.001] [PMID: 20822897]

Chen, E.X.; Hotte, S.; Hirte, H.; Siu, L.L.; Lyons, J.; Squires, M.; Lovell, S.; Turner, S.; McIntosh, L.; Seymour, L. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. Br. J. Cancer, 2014, 111(12), 2262-2267.
[http://dx.doi.org/10.1038/bjc.2014.565] [PMID: 25393368]

Mita, M.M.; Mita, A.C.; Moseley, J.L.; Poon, J.; Small, K.A.; Jou, Y-M.; Kirschmeier, P.; Zhang, D.; Zhu, Y.; Statkevich, P.; Sankhala, K.K.; Sarantopoulos, J.; Cleary, J.M.; Chirieac, L.R.; Rodig, S.J.; Bannerji, R.; Shapiro, G.I. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br. J. Cancer, 2017, 117(9), 1258-1268.
[http://dx.doi.org/10.1038/bjc.2017.288] [PMID: 28859059]

Luke, J.J.; D’Adamo, D.R.; Dickson, M.A.; Keohan, M.L.; Carvajal, R.D.; Maki, R.G.; de Stanchina, E.; Musi, E.; Singer, S.; Schwartz, G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin. Cancer Res., 2012, 18(9), 2638-2647.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-3203] [PMID: 22374332]

Roboz, G.J.; Khoury, H.J.; Shammo, J.M.; Syto, M.; Burrows, F.; Zaknoen, S.L.; Jabbour, E. Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies. J. Clin. Oncol., 2012, 30(15_suppl), 6577-6577.
[http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6577]

Bahleda, R.; Grilley-Olson, J.E.; Govindan, R.; Barlesi, F.; Greillier, L.; Perol, M.; Ray-Coquard, I.; Strumberg, D.; Schultheis, B.; Dy, G.K.; Zalcman, G.; Weiss, G.J.; Walter, A.O.; Kornacker, M.; Rajagopalan, P.; Henderson, D.; Nogai, H.; Ocker, M.; Soria, JC. Phase I dose-escalation studies of roniciclib, a pan-cyclin dependent kinase inhibitor, in advanced malignancies. Br. J. Cancer, 2017, 116(12), 1505-1512.
[http://dx.doi.org/10.1038/bjc.2017.92] [PMID: 28463960]

Blachly, J.S.; Byrd, J.C. Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk. Lymphoma, 2013, 54(10), 2133-2143.
[http://dx.doi.org/10.3109/10428194.2013.783911] [PMID: 23488658]

Legraverend, M.; Tunnah, P.; Noble, M.; Ducrot, P.; Ludwig, O.; Grierson, D.S.; Leost, M.; Meijer, L.; Endicott, J. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem., 2000, 43(7), 1282-1292.
[http://dx.doi.org/10.1021/jm9911130] [PMID: 10753466]

Ibrahim, D.A.; El-Metwally, A.M. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur. J. Med. Chem., 2010, 45(3), 1158-1166.
[http://dx.doi.org/10.1016/j.ejmech.2009.12.026] [PMID: 20045222]

Jacquemard, U.; Dias, N.; Lansiaux, A.; Bailly, C.; Logé, C.; Robert, J-M.; Lozach, O.; Meijer, L.; Mérour, J-Y.; Routier, S. Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5- phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. Bioorg. Med. Chem., 2008, 16(9), 4932-4953.
[http://dx.doi.org/10.1016/j.bmc.2008.03.034] [PMID: 18439832]

Sanchez-Martinez, C.; Shih, C.; Zhu, G.; Li, T.; Brooks, H.B.; Patel, B.K.; Schultz, R.M.; DeHahn, T.B.; Spencer, C.D.; Watkins, S.A.; Ogg, C.A.; Considine, E.; Dempsey, J.A.; Zhang, F. Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4- c]carbazoles versus bis-indolylmaleimides. Bioorg. Med. Chem. Lett., 2003, 13(21), 3841-3846.
[http://dx.doi.org/10.1016/S0960-894X(03)00792-3] [PMID: 14552792]

Dermatakis, A.; Luk, K-C.; DePinto, W. Synthesis of potent oxindole CDK2 inhibitors. Bioorg. Med. Chem., 2003, 11(8), 1873-1881.
[http://dx.doi.org/10.1016/S0968-0896(03)00036-1] [PMID: 12659774]

Misra, R.N.; Xiao, H.Y.; Kim, K.S.; Lu, S.; Han, W-C.; Barbosa, S.A.; Hunt, J.T.; Rawlins, D.B.; Shan, W.; Ahmed, S.Z.N.; Qian, L.; Chen, B.C.; Zhao, R.; Bednarz, M.S.; Kellar, K.A.; Mulheron, J.G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.; Ranadive, S.A.; Sack, J.S.; Tokarski, J.S.; Pavletich, N.P.; Lee, F.Y.; Webster, K.R.; Kimball, S.D. N-(cycloalkylamino)acyl-2- aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5- [[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem., 2004, 47(7), 1719-1728.
[http://dx.doi.org/10.1021/jm0305568] [PMID: 15027863]

Wang, S.; Wood, G.; Meades, C.; Griffiths, G.; Midgley, C.; McNae, I.; McInnes, C.; Anderson, S.; Jackson, W.; Mezna, M.; Yuill, R.; Walkinshaw, M.; Fischer, P.M. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(16), 4237-4240.
[http://dx.doi.org/10.1016/j.bmcl.2004.06.012] [PMID: 15261277]

Shao, H.; Shi, S.; Foley, D.W.; Lam, F.; Abbas, A.Y.; Liu, X.; Huang, S.; Jiang, X.; Baharin, N.; Fischer, P.M.; Wang, S. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti tumour agents. Eur. J. Med. Chem., 2013, 70, 447-455.
[http://dx.doi.org/10.1016/j.ejmech.2013.08.052] [PMID: 24185375]

Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S-Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M.D.; Fischer, P.M. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J. Med. Chem., 2004, 47(7), 1662-1675.
[http://dx.doi.org/10.1021/jm0309957] [PMID: 15027857]

Wang, Y.; Chen, X.; Yan, Y.; Zhu, X.; Liu, M.; Liu, X. Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4- diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity. J. Med. Chem., 2020, 63(6), 3327-3347.
[http://dx.doi.org/10.1021/acs.jmedchem.9b02121] [PMID: 32129996]

Heathcote, D.A.; Patel, H.; Kroll, S.H.B.; Hazel, P.; Periyasamy, M.; Alikian, M.; Kanneganti, S.K.; Jogalekar, A.S.; Scheiper, B.; Barbazanges, M.; Blum, A.; Brackow, J.; Siwicka, A.; Pace, R.D.M.; Fuchter, M.J.; Snyder, J.P.; Liotta, D.C.; Freemont, P.S.; Aboagye, E.O.; Coombes, R.C.; Barrett, A.G.M.; Ali, S. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. J. Med. Chem., 2010, 53(24), 8508-8522.
[http://dx.doi.org/10.1021/jm100732t] [PMID: 21080703]

Nie, Z.; Perretta, C.; Erickson, P.; Margosiak, S.; Lu, J.; Averill, A.; Almassy, R.; Chu, S. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg. Med. Chem. Lett., 2008, 18(2), 619-623.
[http://dx.doi.org/10.1016/j.bmcl.2007.11.074] [PMID: 18055206]

Lukasik, P.M.; Elabar, S.; Lam, F.; Shao, H.; Liu, X.; Abbas, A.Y.; Wang, S. Synthesis and biological evaluation of imidazo[4,5- b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents. Eur. J. Med. Chem., 2012, 57, 311-322.
[http://dx.doi.org/10.1016/j.ejmech.2012.09.034] [PMID: 23085105]

Moravcová, D.; Kryštof, V.; Havlícek, L.; Moravec, J.; Lenobel, R.; Strnad, M. Pyrazolo[4,3-d]pyrimidines as new generation of cyclin dependent kinase inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(18), 2989-2992.
[http://dx.doi.org/10.1016/S0960-894X(03)00631-0] [PMID: 12941318]

Dwyer, M.P.; Paruch, K.; Alvarez, C.; Doll, R.J.; Keertikar, K.; Duca, J.; Fischmann, T.O.; Hruza, A.; Madison, V.; Lees, E.; Parry, D.; Seghezzi, W.; Sgambellone, N.; Shanahan, F.; Wiswell, D.; Guzi, T.J. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(22), 6216-6219.
[http://dx.doi.org/10.1016/j.bmcl.2007.09.018] [PMID: 17904366]

Wang, Y.; Chen, Y.; Cheng, X.; Zhang, K.; Wang, H.; Liu, B.; Wang, J. Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells. Bioorg. Med. Chem., 2018, 26(12), 3491-3501.
[http://dx.doi.org/10.1016/j.bmc.2018.05.024] [PMID: 29853338]

Gray, N.; Détivaud, L.; Doerig, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem., 1999, 6(9), 859-875.
[PMID: 10495356]

Trova, M.P.; Barnes, K.D.; Barford, C.; Benanti, T.; Bielaska, M.; Burry, L.; Lehman, J.M.; Murphy, C.; O’Grady, H.; Peace, D.; Salamone, S.; Smith, J.; Snider, P.; Toporowski, J.; Tregay, S.; Wilson, A.; Wyle, M.; Zheng, X.; Friedrich, T.D. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I. Bioorg. Med. Chem. Lett., 2009, 19(23), 6608-6612.
[http://dx.doi.org/10.1016/j.bmcl.2009.10.025] [PMID: 19846305]

Trova, M.P.; Barnes, K.D.; Alicea, L.; Benanti, T.; Bielaska, M.; Bilotta, J.; Bliss, B.; Duong, T.N.; Haydar, S.; Herr, R.J.; Hui, Y.; Johnson, M.; Lehman, J.M.; Peace, D.; Rainka, M.; Snider, P.; Salamone, S.; Tregay, S.; Zheng, X.; Friedrich, T.D. Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II. Bioorg. Med. Chem. Lett., 2009, 19(23), 6613-6617.
[http://dx.doi.org/10.1016/j.bmcl.2009.10.011] [PMID: 19854650]

Moravec, J.; Kryštof, V.; Hanuš, J.; Havlícek, L.; Moravcová, D.; Fuksová, K.; Kuzma, M.; Lenobel, R.; Otyepka, M.; Strnad, M. 2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(18), 2993-2996.
[http://dx.doi.org/10.1016/S0960-894X(03)00632-2] [PMID: 12941319]

Vandromme, L.; Piguel, S.; Lozach, O.; Meijer, L.; Legraverend, M.; Grierson, D.S. Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(12), 3144-3146.
[http://dx.doi.org/10.1016/j.bmcl.2006.03.060] [PMID: 16616489]

Sun, J.; Lv, X-H.; Qiu, H-Y.; Wang, Y-T.; Du, Q-R.; Li, D-D.; Yang, Y-H.; Zhu, H-L. Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors. Eur. J. Med. Chem., 2013, 68, 1-9.
[http://dx.doi.org/10.1016/j.ejmech.2013.07.003] [PMID: 23933045]

Lin, R.; Chiu, G.; Yu, Y.; Connolly, P.J.; Li, S.; Lu, Y.; Adams, M.; Fuentes-Pesquera, A.R.; Emanuel, S.L.; Greenberger, L.M. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(16), 4557-4561.
[http://dx.doi.org/10.1016/j.bmcl.2007.05.092] [PMID: 17574416]

Jorda, R.; Schütznerová, E.; Cankař, P.; Brychtová, V.; Navrátilová, J.; Kryštof, V. Novel arylazopyrazole inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem., 2015, 23(9), 1975-1981.
[http://dx.doi.org/10.1016/j.bmc.2015.03.025] [PMID: 25835357]

Kryštof, V.; Cankař, P.; Frysová, I.; Slouka, J.; Kontopidis, G.; Dzubák, P.; Hajdúch, M.; Srovnal, J.; de Azevedo, W.F., Jr; Orság, M.; Paprskárová, M.; Rolcík, J.; Látr, A.; Fischer, P.M.; Strnad, M. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J. Med. Chem., 2006, 49(22), 6500-6509.
[http://dx.doi.org/10.1021/jm0605740] [PMID: 17064068]

Havlicek, L.; Fuksova, K.; Krystof, V.; Orsag, M.; Vojtesek, B.; Strnad, M. 8-Azapurines as new inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem., 2005, 13(18), 5399-5407.
[http://dx.doi.org/10.1016/j.bmc.2005.06.007] [PMID: 15993080]

Trova, M.P. 6-Substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents. U.S. Patent 6,627,633, September 23, 2003.

Akué-Gédu, R.; Letribot, B.; Saugues, E.; Debiton, E.; Anizon, F.; Moreau, P. Kinase inhibitory potencies and in vitro antiproliferative activities of N-10 substituted pyrrolo[2,3-a]carbazole derivatives. Bioorg. Med. Chem. Lett., 2012, 22(11), 3807-3809.
[http://dx.doi.org/10.1016/j.bmcl.2012.03.098] [PMID: 22543026]

Wyatt, P.G.; Woodhead, A.J.; Berdini, V.; Boulstridge, J.A.; Carr, M.G.; Cross, D.M.; Davis, D.J.; Devine, L.A.; Early, T.R.; Feltell, R.E.; Lewis, E.J.; McMenamin, R.L.; Navarro, E.F.; O’Brien, M.A.; O’Reilly, M.; Reule, M.; Saxty, G.; Seavers, L.C.; Smith, D.M.; Squires, M.S.; Trewartha, G.; Walker, M.T.; Woolford, A.J. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)- 1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J. Med. Chem., 2008, 51(16), 4986-4999.
[http://dx.doi.org/10.1021/jm800382h] [PMID: 18656911]

Brasca, M.G.; Albanese, C.; Amici, R.; Ballinari, D.; Corti, L.; Croci, V.; Fancelli, D.; Fiorentini, F.; Nesi, M.; Orsini, P.; Orzi, F.; Pastori, W.; Perrone, E.; Pesenti, E.; Pevarello, P.; Riccardi-Sirtori, F.; Roletto, F.; Roussel, P.; Varasi, M.; Vulpetti, A.; Mercurio, C. 6-Substituted pyrrolo[3,4-c]pyrazoles: an improved class of CDK2 inhibitors. ChemMedChem, 2007, 2(6), 841-852.
[http://dx.doi.org/10.1002/cmdc.200600302] [PMID: 17450625]

Brasca, M.G.; Albanese, C.; Alzani, R.; Amici, R.; Avanzi, N.; Ballinari, D.; Bischoff, J.; Borghi, D.; Casale, E.; Croci, V.; Fiorentini, F.; Isacchi, A.; Mercurio, C.; Nesi, M.; Orsini, P.; Pastori, W.; Pesenti, E.; Pevarello, P.; Roussel, P.; Varasi, M.; Volpi, D.; Vulpetti, A.; Ciomei, M. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg. Med. Chem., 2010, 18(5), 1844-1853.
[http://dx.doi.org/10.1016/j.bmc.2010.01.042] [PMID: 20153204]

Pevarello, P.; Fancelli, D.; Vulpetti, A.; Amici, R.; Villa, M.; Pittalà, V.; Vianello, P.; Cameron, A.; Ciomei, M.; Mercurio, C.; Bischoff, J.R.; Roletto, F.; Varasi, M.; Brasca, M.G. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(4), 1084-1090.
[http://dx.doi.org/10.1016/j.bmcl.2005.10.071] [PMID: 16290148]

Bai, X-G.; Yu, D-K.; Wang, J-X.; Zhang, H.; He, H-W.; Shao, RG.; Li, X-M.; Wang, Y-C. Design, synthesis and anticancer activity of 1-acyl-3-amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives. Bioorg. Med. Chem. Lett., 2012, 22(22), 6947-6951.
[http://dx.doi.org/10.1016/j.bmcl.2012.08.117] [PMID: 23036956]

Engler, T.A.; Furness, K.; Malhotra, S.; Sanchez-Martinez, C.; Shih, C.; Xie, W.; Zhu, G.; Zhou, X.; Conner, S.; Faul, M.M.; Sullivan, K.A.; Kolis, S.P.; Brooks, H.B.; Patel, B.; Schultz, R.M.; DeHahn, T.B.; Kirmani, K.; Spencer, C.D.; Watkins, S.A.; Considine, E.L.; Dempsey, J.A.; Ogg, C.A.; Stamm, N.B.; Anderson, B.D.; Campbell, R.M.; Vasudevan, V.; Lytle, M.L. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7- a]pyrrolo[3,4-c]carbazoles. Bioorg. Med. Chem. Lett., 2003, 13(14), 2261-2267.
[http://dx.doi.org/10.1016/S0960-894X(03)00461-X] [PMID: 12824014]

Fousteris, M.A.; Papakyriakou, A.; Koutsourea, A.; Manioudaki, M.; Lampropoulou, E.; Papadimitriou, E.; Spyroulias, G.A.; Nikolaropoulos, S.S. Pyrrolo[2,3-a]carbazoles as potential cyclin dependent kinase 1 (CDK1) Inhibitors. Synthesis, biological evaluation, and binding mode through docking simulations. J. Med. Chem., 2008, 51(4), 1048-1052.
[http://dx.doi.org/10.1021/jm0700666] [PMID: 18232654]

Zhu, G.; Conner, S.; Zhou, X.; Shih, C.; Brooks, H.B.; Considine, E.; Dempsey, J.A.; Ogg, C.; Patel, B.; Schultz, R.M.; Spencer, C.D.; Teicher, B.; Watkins, S.A. Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(7), 1231-1235.
[http://dx.doi.org/10.1016/S0960-894X(03)00133-1] [PMID: 12657252]

Sanchez-Martinez, C.; Shih, C.; Faul, M.M.; Zhu, G.; Paal, M.; Somoza, C.; Li, T.; Kumrich, C.A.; Winneroski, L.L.; Xun, Z.; Brooks, H.B.; Patel, B.K.; Schultz, R.M.; DeHahn, T.B.; Spencer, C.D.; Watkins, S.A.; Considine, E.; Dempsey, J.A.; Ogg, C.A.; Campbell, R.M.; Anderson, B.A.; Wagner, J. Aryl[a]pyrrolo[3,4- c]carbazoles as selective cyclin D1-CDK4 inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(21), 3835-3839.
[http://dx.doi.org/10.1016/S0960-894X(03)00791-1] [PMID: 14552791]

Faul, M.M.; Engler, T.A.; Sullivan, K.A.; Grutsch, J.L.; Clayton, M.T.; Martinelli, M.J.; Pawlak, J.M.; LeTourneau, M.; Coffey, D.S.; Pedersen, S.W.; Kolis, S.P.; Furness, K.; Malhotra, S.; Alawar, R.S.; Ray, J.E. Synthetic approaches to indolo[6,7- a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors. J. Org. Chem., 2004, 69(9), 2967-2975.
[http://dx.doi.org/10.1021/jo035606v] [PMID: 15104433]

Veselý, J.; Havliček, L.; Strnad, M.; Blow, J.J.; Donella-Deana, A.; Pinna, L.; Letham, D.S.; Kato, J.; Detivaud, L.; Leclerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem., 1994, 224(2), 771-786.
[http://dx.doi.org/10.1111/j.1432-1033.1994.00771.x] [PMID: 7925396]

Meijer, L.; Borgne, A.; Mulner, O.; Chong, J.P.J.; Blow, J.J.; Inagaki, N.; Inagaki, M.; Delcros, J-G.; Moulinoux, J-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 1997, 243(1-2), 527-536.
[http://dx.doi.org/10.1111/j.1432-1033.1997.t01-2-00527.x] [PMID: 9030781]

Chang, Y-T.; Gray, N.S.; Rosania, G.R.; Sutherlin, D.P.; Kwon, S.; Norman, T.C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P.G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol., 1999, 6(6), 361-375.
[http://dx.doi.org/10.1016/S1074-5521(99)80048-9] [PMID: 10375538]

Jain, S.K.; Bharate, S.B.; Vishwakarma, R.A. Cyclin-dependent kinase inhibition by flavoalkaloids. Mini Rev. Med. Chem., 2012, 12(7), 632-649.
[http://dx.doi.org/10.2174/138955712800626683] [PMID: 22512551]

U.S. National Library of Medicine Available from:. https://clinicaltrials.gov/ct2/results?term=flavopiridol2020. (Feb 02, 2020).

Meijer, L.; Thunnissen, A.M.; White, A.W.; Garnier, M.; Nikolic, M.; Tsai, L.H.; Walter, J.; Cleverley, K.E.; Salinas, P.C.; Wu, Y.Z.; Biernat, J.; Mandelkow, E.M.; Kim, S.H.; Pettit, G.R. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol., 2000, 7(1), 51-63.
[http://dx.doi.org/10.1016/S1074-5521(00)00063-6] [PMID: 10662688]

Soni, R.; Muller, L.; Furet, P.; Schoepfer, J.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Chaudhuri, B. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun., 2000, 275(3), 877-884.
[http://dx.doi.org/10.1006/bbrc.2000.3349] [PMID: 10973815]

Bharate, S.B.; Manda, S.; Mupparapu, N.; Battini, N.; Vishwakarma, R.A. Chemistry and biology of fascaplysin, a potent marine-derived CDK-4 inhibitor. Mini Rev. Med. Chem., 2012, 12(7), 650-664.
[http://dx.doi.org/10.2174/138955712800626719] [PMID: 22512549]

Gompel, M.; Leost, M.; De Kier Joffe, E.B.; Puricelli, L.; Franco, L.H.; Palermo, J.; Meijer, L. Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. Bioorg. Med. Chem. Lett., 2004, 14(7), 1703-1707.
[http://dx.doi.org/10.1016/j.bmcl.2004.01.050] [PMID: 15026054]

Bharate, S.B.; Yadav, R.R.; Battula, S.; Vishwakarma, R.A. Meridianins: marine-derived potent kinase inhibitors. Mini Rev. Med. Chem., 2012, 12(7), 618-631.
[http://dx.doi.org/10.2174/138955712800626728] [PMID: 22512550]

Simone, M.; Erba, E.; Damia, G.; Vikhanskaya, F.; Di Francesco, A.M.; Riccardi, R.; Bailly, C.; Cuevas, C.; Fernandez Sousa-Faro, J.M.; D’Incalci, M. Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity. Eur. J. Cancer, 2005, 41(15), 2366-2377.
[http://dx.doi.org/10.1016/j.ejca.2005.05.015] [PMID: 16181779]

Kobayashi, J.i.; Suzuki, M.; Tsuda, M. Konbu’acidin A, a new bromopyrrole alkaloid with cdk4 inhibitory activity from Hymeniacidon sponge. Tetrahedron, 1997, 53(46), 15681-15684.
[http://dx.doi.org/10.1016/S0040-4020(97)10022-9]

Tamaoki, T. Use and specificity of staurosporine, UCN-O1, and calphostin C as protein kinase inhibitors. Methods Enzymol; Academic Press: Cambridge, 1991, Vol. 201, pp. 340-347.
[http://dx.doi.org/10.1016/0076-6879(91)01030-6]

Tamaoki, T.; Nomoto, H.; Takahashi, I.; Kato, Y.; Morimoto, M.; Tomita, F. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem. Biophys. Res. Commun., 1986, 135(2), 397-402.
[http://dx.doi.org/10.1016/0006-291X(86)90008-2] [PMID: 3457562]

Gadbois, D.M.; Hamaguchi, J.R.; Swank, R.A.; Bradbury, E.M. Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem. Biophys. Res. Commun., 1992, 184(1), 80-85.
[http://dx.doi.org/10.1016/0006-291X(92)91160-R] [PMID: 1567459]

Gadbois, D.M.; Crissman, H.A.; Tobey, R.A.; Bradbury, E.M. Multiple kinase arrest points in the G1 phase of nontransformed mammalian cells are absent in transformed cells. Proc. Natl. Acad. Sci. USA, 1992, 89(18), 8626-8630.
[http://dx.doi.org/10.1073/pnas.89.18.8626] [PMID: 1528872]

Gali-Muhtasib, H.; Bakkar, N. Modulating cell cycle: current applications and prospects for future drug development. Curr. Cancer Drug Targets, 2002, 2(4), 309-336.
[http://dx.doi.org/10.2174/1568009023333809] [PMID: 12470209]

Flaherty, K.T.; Lorusso, P.M.; Demichele, A.; Abramson, V.G.; Courtney, R.; Randolph, S.S.; Shaik, M.N.; Wilner, K.D.; O’Dwyer, P.J.; Schwartz, G.K.; Phase, I. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin. Cancer Res., 2012, 18(2), 568-576.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-0509] [PMID: 22090362]

Lynce, F.; Shajahan-Haq, A.N.; Swain, S.M. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. Pharmacol. Ther., 2018, 191, 65-73.
[http://dx.doi.org/10.1016/j.pharmthera.2018.06.008] [PMID: 29933034]

Malumbres, M.; Pevarello, P.; Barbacid, M.; Bischoff, J.R. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci., 2008, 29(1), 16-21.
[http://dx.doi.org/10.1016/j.tips.2007.10.012] [PMID: 18054800]

Malumbres, M.; Barbacid, M. Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell, 2006, 9(1), 2-4.
[http://dx.doi.org/10.1016/j.ccr.2005.12.026] [PMID: 16413464]

Kwong, L.N.; Costello, J.C.; Liu, H.; Jiang, S.; Helms, T.L.; Langsdorf, A.E.; Jakubosky, D.; Genovese, G.; Muller, F.L.; Jeong, J.H.; Bender, R.P.; Chu, G.C.; Flaherty, K.T.; Wargo, J.A.; Collins, J.J.; Chin, L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med., 2012, 18(10), 1503-1510.
[http://dx.doi.org/10.1038/nm.2941] [PMID: 22983396]

Franco, J.; Witkiewicz, A.K.; Knudsen, E.S. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget, 2014, 5(15), 6512-6525.
[http://dx.doi.org/10.18632/oncotarget.2270] [PMID: 25156567]

Heilmann, A.M.; Perera, R.M.; Ecker, V.; Nicolay, B.N.; Bardeesy, N.; Benes, C.H.; Dyson, N.J. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res., 2014, 74(14), 3947-3958.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-2923] [PMID: 24986516]

Cortés, J.; Im, S.A.; Holgado, E.; Perez-Garcia, J.M.; Schmid, P.; Chavez-MacGregor, M. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treat. Rev., 2017, 61, 53-60.
[http://dx.doi.org/10.1016/j.ctrv.2017.09.011] [PMID: 29100169]

Whittaker, S.; Madani, D.; Joshi, S.; Chung, S.A.; Johns, T.; Day, B.; Khasraw, M.; McDonald, K.L. Combination of palbociclib and radiotherapy for glioblastoma. Cell Death Discov., 2017, 3(1), 17033.
[http://dx.doi.org/10.1038/cddiscovery.2017.33] [PMID: 28690875]